Vanguard Group’s CervoMed CRVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2.8M | Buy |
354,950
+11,487
| +3% | +$92.3K | ﹤0.01% | 3453 |
|
|
2025
Q3 | $2.78M | Buy |
343,463
+3,445
| +1% | +$29.6K | ﹤0.01% | 3471 |
|
|
2025
Q2 | $2.14M | Sell |
340,018
-38,644
| -10% | -$329K | ﹤0.01% | 3517 |
|
|
2025
Q1 | $3.46M | Sell |
378,662
-4,825
| -1% | -$18.4K | ﹤0.01% | 3303 |
|
|
2024
Q4 | $897K | Sell |
383,487
-16,812
| -4% | -$163K | ﹤0.01% | 3798 |
|
|
2024
Q3 | $5.84M | Sell |
400,299
-8,476
| -2% | -$131K | ﹤0.01% | 3208 |
|
|
2024
Q2 | $7M | Buy |
408,775
+381,483
| +1,398% | +$8.34M | ﹤0.01% | 3099 |
|
|
2024
Q1 | $636K | Buy |
27,292
+7,376
| +37% | +$98.4K | ﹤0.01% | 3955 |
|
|
2023
Q4 | $152K | Hold |
19,916
| – | – | ﹤0.01% | 4255 |
|
|
2023
Q3 | $92K | Sell |
19,916
-24,239
| -55% | -$122K | ﹤0.01% | 4357 |
|
|
2023
Q2 | $221K | Sell |
44,155
-4,354
| -9% | -$25.3K | ﹤0.01% | 4297 |
|
|
2023
Q1 | $302K | Hold |
48,509
| – | – | ﹤0.01% | 4248 |
|
|
2022
Q4 | $368K | Buy |
48,509
+28
| +0.1% | +$233 | ﹤0.01% | 4180 |
|
|
2022
Q3 | $389K | Sell |
48,481
-4,832
| -9% | -$49K | ﹤0.01% | 4284 |
|
|
2022
Q2 | $534K | Sell |
53,313
-2
| -0% | -$25 | ﹤0.01% | 4275 |
|
|
2022
Q1 | $999K | Sell |
53,315
-7,944
| -13% | -$158K | ﹤0.01% | 4208 |
|
|
2021
Q4 | $1.4M | Sell |
61,259
-291
| -0.5% | -$9.1K | ﹤0.01% | 4166 |
|
|
2021
Q3 | $2.35M | Buy |
61,550
+124
| +0.2% | +$5.16K | ﹤0.01% | 4014 |
|
|
2021
Q2 | $3.36M | Buy |
61,426
+6,481
| +12% | +$358K | ﹤0.01% | 3788 |
|
|
2021
Q1 | $3.78M | Buy |
54,945
+49,702
| +948% | +$4.17M | ﹤0.01% | 3667 |
|
|
2020
Q4 | $312K | Buy |
5,243
+546
| +12% | +$32K | ﹤0.01% | 4032 |
|
|
2020
Q3 | $297K | Buy |
4,697
+457
| +11% | +$34.7K | ﹤0.01% | 3904 |
|
|
2020
Q2 | $310K | Buy |
4,240
+3,875
| +1,062% | +$236K | ﹤0.01% | 3861 |
|
|
2020
Q1 | $9K | Hold |
365
| – | – | ﹤0.01% | 4071 |
|
|
2019
Q4 | $13K | Sell |
365
-610
| -63% | -$37.3K | ﹤0.01% | 4108 |
|
|
2019
Q3 | $135K | Buy |
975
+449
| +85% | +$72.5K | ﹤0.01% | 4002 |
|
|
2019
Q2 | $112K | Sell |
526
-130
| -20% | -$35K | ﹤0.01% | 4043 |
|
|
2019
Q1 | $183K | Buy |
656
+71
| +12% | +$17K | ﹤0.01% | 3939 |
|
|
2018
Q4 | $87K | Sell |
585
-210
| -26% | -$71.6K | ﹤0.01% | 4011 |
|
|
2018
Q3 | $386K | Sell |
795
-23
| -3% | -$10.7K | ﹤0.01% | 3893 |
|
|
2018
Q2 | $421K | Buy |
818
+14
| +2% | +$8.28K | ﹤0.01% | 3849 |
|
|
2018
Q1 | $494K | Buy |
804
+601
| +296% | +$521K | ﹤0.01% | 3789 |
|
|
2017
Q4 | $272K | Buy |
203
+88
| +77% | +$143K | ﹤0.01% | 3875 |
|
|
2017
Q3 | $214K | Buy |
115
+21
| +22% | +$43.4K | ﹤0.01% | 3902 |
|
|
2017
Q2 | $247K | Buy |
94
+34
| +57% | +$110K | ﹤0.01% | 3864 |
|
|
2017
Q1 | $270K | Buy |
+60
| New | +$258K | ﹤0.01% | 3856 |
|
Other funds holding CRVO
AIC
CFG
PWM
Vanguard Group's CRVO Position: Q4 2025 in Review
Vanguard Group increased its CervoMed (CRVO) stake by 3.3% in Q4 2025, buying an estimated $92.3K and bringing the position to 354,950 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3453.
Vanguard Group first reported a position in CRVO in Q1 2017 and has held it in 36 quarters since. The position peaked at $7M in Q2 2024. 48 funds tracked by Wall St. Rank hold CRVO as of Q4 2025.
- Vanguard Group held 354,950 shares of CervoMed worth $2.8M as of Q4 2025.
- Vanguard Group bought 11,487 CervoMed shares in Q4 2025, an estimated $92.3K.
- CervoMed made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3453 holding.
- Vanguard Group first reported a position in CervoMed in Q1 2017 and has held it in 36 quarters since.
- Vanguard Group's CervoMed position peaked at $7M in Q2 2024.
- 48 funds tracked by Wall St. Rank held CervoMed as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.